[MO3] Mini-Oral Session 3　Gastrointestinal Cancer 1（Upper GI Tract 1）
【E】

[MO3-1] Randomized phase II study of DTX versus PTX in patients with ESCC refractory to 5-FU- and platinum-based chemotherapy

^○Takashi Ohta¹, Sachiko Yamamoto², Takayuki Kii³, Hiroki Hara⁴, Ryohei Kawabata^5,6, Junji Kawada⁷, Atsushi Takeno⁸, Jin Matsuyama⁹, Shugo Ueda¹⁰, Hisato Kawakami¹¹, Yoshihiro Okita^12,13, Shunji Endo¹⁴, Yutaka Kimura^6,15, Kazuhiro Yanagihara¹⁶, Tatsuya Okuno¹⁷, Yukinori Kurokawa¹⁸, Toshio Shimokawa¹⁹, Taroh Satoh²⁰ (1.Department of Clinical Oncology / Department of Gastroenterology, Kansai Rosai Hospital, 2.Department of Gastrointestinal Oncology, Osaka International Cancer Institute, 3.Cancer Chemotherapy Center, Osaka Medical and Pharmaceutical University, 4.Department of Gastroenterology, Saitama Cancer Center, 5.Department of Surgery, Osaka Rosai Hospital, 6.Department of Surgery, Sakai City Medical Center, 7.Department of Surgery, Osaka General Medical Center, 8.Department of Surgery, Kansai Rosai Hospital, 9.Department of Surgery, Yao Municipal Hospital, 10.Department of Gastroenterological Surgery and Oncology, Kitano Hospital, Tazuke Kofukai Medical Research Institute, 11.Department of Medical Oncology, Kindai University Faculty of Medicine, 12.Department of Medical Oncology, Kobe City Medical Center General Hospital, 13.Department of Clinical Oncology, Kagawa University Faculty of Medicine, 14.Department of Gastroenterological Surgery, Higashiosaka City Medical Center, 15.Department of Surgery, Kindai University Faculty of Medicine, 16.Department of Medical Oncology, Kansai Electric Power Hospital, 17.Division of Gastroenterology, Department of Internal Medicine, Graduate School of Medicine, Kobe University, 18.Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, 19.Department of Medical Data Science, Graduate School of Medicine, Wakayama Medical University, 20.Department of Frontier Science for Cancer and Chemotherapy, Osaka University Graduate School of Medicine)